{"title":"磺脲类药物作为糖尿病的治疗选择:进展如何?","authors":"Manta A, Peppa M","doi":"10.15761/DU.1000124","DOIUrl":null,"url":null,"abstract":"Received: March 21, 2019; Accepted: April 01, 2019; Published: April 04, 2019 Sulfonylureas (SUs) constitute a hallmark in the treatment of Diabetes Mellitus Type 2 (DM2) and have remained the main pharmacological approach for many decades. Tolbutamide and the rest of the first-generation SUs were originated in Germany in the 1950s, while the second-generation agents such as glyburide and glipizide were released in the United States in 1984 [1]. Glimepiride, a thirdgeneration SU, became available in the United States in 1995 [2]. In 1997, SUs was the most prescribed class of oral antidiabetic agents, corresponding to over 60% of all treatment visits [3].","PeriodicalId":309709,"journal":{"name":"Diabetes Updates","volume":"43 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Sulfonylureas as treatment choice in Diabetes Mellitus : Where are we now?\",\"authors\":\"Manta A, Peppa M\",\"doi\":\"10.15761/DU.1000124\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Received: March 21, 2019; Accepted: April 01, 2019; Published: April 04, 2019 Sulfonylureas (SUs) constitute a hallmark in the treatment of Diabetes Mellitus Type 2 (DM2) and have remained the main pharmacological approach for many decades. Tolbutamide and the rest of the first-generation SUs were originated in Germany in the 1950s, while the second-generation agents such as glyburide and glipizide were released in the United States in 1984 [1]. Glimepiride, a thirdgeneration SU, became available in the United States in 1995 [2]. In 1997, SUs was the most prescribed class of oral antidiabetic agents, corresponding to over 60% of all treatment visits [3].\",\"PeriodicalId\":309709,\"journal\":{\"name\":\"Diabetes Updates\",\"volume\":\"43 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes Updates\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15761/DU.1000124\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Updates","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/DU.1000124","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Sulfonylureas as treatment choice in Diabetes Mellitus : Where are we now?
Received: March 21, 2019; Accepted: April 01, 2019; Published: April 04, 2019 Sulfonylureas (SUs) constitute a hallmark in the treatment of Diabetes Mellitus Type 2 (DM2) and have remained the main pharmacological approach for many decades. Tolbutamide and the rest of the first-generation SUs were originated in Germany in the 1950s, while the second-generation agents such as glyburide and glipizide were released in the United States in 1984 [1]. Glimepiride, a thirdgeneration SU, became available in the United States in 1995 [2]. In 1997, SUs was the most prescribed class of oral antidiabetic agents, corresponding to over 60% of all treatment visits [3].
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
